Transdermal Patch Organic Acid Diclofenac Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, such as transdermal diclofenac patches, face challenges in achieving effective and safe drug release and skin permeability, necessitating the development of a patch with improved formulations.
Innovation Solution
A patch comprising a backing layer and an adhesive layer with diclofenac sodium, dimethyl sulfoxide, and an organic acid, where the organic acid content is 6-8% of the adhesive layer's total mass, applied once daily to provide a dose of 70-150 mg diclofenac sodium, enhancing skin permeability and preventing crystal precipitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a high concentration of diclofenac sodium is used in the adhesive layer, then the therapeutic effect is improved, but the risk of crystal precipitation and skin irritation increases
Solution Approach 1:
Dimethyl sulfoxide (DMSO) is used as a penetration enhancer and solvent intermediary that facilitates the dissolution of diclofenac sodium and prevents crystal precipitation. The organic acid component acts as another intermediary that maintains drug solubility in the adhesive matrix, allowing high drug concentrations without precipitation or excessive irritation.
Solution Approach 2:
The patent optimizes the concentration of organic acid to 6-8 mass% and DMSO to 5-10 mass% in the adhesive layer. These parameter changes create an optimal chemical environment that maintains diclofenac sodium solubility at high concentrations while controlling skin permeability to prevent irritation.
2Ease of operation
If the organic acid content is increased to improve skin permeability, then drug absorption is enhanced, but the risk of skin irritation increases
Solution Approach 1:
The organic acid content is precisely controlled within 6-8 mass% of the adhesive layer total mass. This optimized parameter range provides sufficient skin permeability enhancement while maintaining safety margins below irritation thresholds. The balanced formulation achieves effective drug delivery without excessive acidity that would cause irritation.
3Reliability
If the patch is applied frequently to maintain therapeutic levels, then efficacy is improved, but patient compliance and safety decrease due to cumulative exposure
Solution Approach 1:
The patch is designed for once-daily application, creating a periodic dosing regimen that maintains therapeutic drug levels while allowing sufficient elimination time between doses. This periodic action pattern prevents cumulative toxicity while ensuring continuous therapeutic effect throughout the day.
Solution Approach 2:
The controlled-release adhesive matrix provides continuous drug delivery over 24 hours, ensuring uninterrupted therapeutic action at the application site. This continuous local action maintains effective concentrations without requiring frequent reapplication, thereby preventing cumulative systemic exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch effectively alleviates osteoarthritis pain, particularly for knee osteoarthritis, with optimal pharmacokinetic parameters including maximum plasma concentration, half-life, and area under plasma concentration-time curve, ensuring safety and efficacy in treating osteoarthritis.
Implementation Method 1
dimethyl sulfoxide, wherein a content of the organic acid is 6 mass % to 8 mass % with respect to a total mass of the adhesive layer
Implementation Method 2
an organic acid, wherein a content of the organic acid is 6 mass % to 8 mass % with respect to a total mass of the adhesive layer
Data Source
AI summary
Disclosed is a transdermal patch for treating osteoarthritis. The transdermal patch comprises a support layer and an adhesive layer laminated on the support layer. The adhesive layer includes an adhesive base, diclofenac sodium, dimethyl sulfoxide, and an organic acid. The organic acid content is 6-8 mass % of the total mass of the adhesive layer. The transdermal patch is applied once daily to an affected part and the dosage of diclofenac sodium per application is 70-150 mg.